Brepocitinib Overview & RVT-3101 Update

VTAMA Is Just Getting Started Penetrating 400,000+ TRX Weekly Topical Market' Psoriasis and Atopic Dermatitis Total Market - Weekly TRX2 Psoriasis 600,000 VTAMA approved indication 500,000 400,000 300,000 200,000 100,000 3,922 VTAMA (tapinarof) cream 1% 65,703 161,487 91,862 Topicals Atopic Dermatitis VTAMA Phase 3 data expected 1H 2023 Total 35,825 356,749 518,236 320,924 Systemics Total Topicals Systemics Total Grand Total roivant 1. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. 2. Source: IQVIA National Prescription Audit (NPA). Market data as of week ending 09/16/2022. VTAMA TRX as of 12/23/2022. Psoriasis market weekly TRxs factored at the product level using ICD-10 code claim analytics. Topical Steroid Other Topical Biologic Oral 20 20 For investor audiences only

View entire presentation